

HYPOVITAMINOSIS D: A NEW RISK MARKER FOR CARDIOVASCULAR DISEASE

JOSEPH P MCCONNELL, KEVIN F FOLEY, GINA M VARGAS

INDEX TERMS: vitamin D, cholecalciferol, hypovitaminosis, 25-hydroxyvitamin D.

LEARNING OBJECTIVES

1. Differentiate and define the various forms of vitamin-D, including Vitamin D₂, D₃ 25(OH)D and 1,25(OH)₂D.
2. Describe current opinion concerning vitamin-D dosing recommendations as well as issues around establishing a normal reference range.
3. Identify several diseases and pathologies for which hypovitaminosis D has been implicated.
4. Explain the correlations between serum 25(OH)D levels and the cardiovascular risk factors of hypertension and metabolic syndrome.
5. Describe the overall relationship between hypovitaminosis D and cardiovascular disease and the need for future studies to demonstrate causality.

Clin Lab Sci 2009;22(4);240

Joseph P. McConnell PhD, is director, Cardiovascular

The Focus section seeks to publish relevant and timely continuing education for clinical laboratory practitioners. Section editors, topics, and authors are selected in advance to cover current areas of interest in each discipline. Readers can obtain continuing education credit (CE) through P.A.C.E.[®] by completing the continuing education registration form, recording answers to the examination, and mailing a photocopy of it with the appropriate fee to the address designated on the form. Suggestions for future Focus topics and authors, and manuscripts appropriate for CE credit are encouraged. Direct all inquiries to the Clin Lab Sci Editorial Office, Westminster Publishers, 315 Westminster Court, Brandon MS 39047. (601) 214-5028, (202) 315-5843 (fax). westminsterpublishers@comcast.net.

Laboratory Medicine, The Mayo Clinic and Foundation, Rochester, MN.

Kevin F. Foley PhD, MT is a clinical chemist, Kaiser Permanente NW Laboratories, Portland, OR.

Gina M. Vargas PhD, is director, Importadora y Laboratorio Clinico ATM SRL: Cochabamba, Bolivia

Address for Correspondence: *Joseph P. McConnell PhD, Mayo Clinic; Cardiovascular Laboratory Medicine, Rochester, Minnesota, (507) 284-0524, Fax: (507) 266-2888, Email: mconnell.joseph@mayo.edu*

INTRODUCTION

Vitamin D has a well-established role in calcium and phosphorus metabolism and bone mineralization. Vitamin D deficiency causes rickets in children, and in adults can lead to osteomalacia, resulting in muscle and bone weakness. Data are emerging that link hypovitaminosis D, as assessed by measurement of 25-hydroxyvitamin D [25(OH)D], with cardiovascular pathology. Vitamin D deficiency has been associated with hypertension, some inflammatory markers, and metabolic syndrome. More recently, low serum 25(OH)D has been associated with increased incidence of cardiovascular events and all-cause mortality. In this review, we discuss the role of vitamin D in health, and describe recent evidence linking hypovitaminosis D to cardiovascular disease. We describe controversies surrounding recommended daily intake and optimal serum levels, as well as discuss the need for further research relating vitamin D deficiency with cardiovascular disease.

Vitamin D deficiency

Vitamin D, which has also been referred to as the “sunshine vitamin” is a lipid-soluble vitamin obtained from both exogenous and endogenous sources. Some

FOCUS: CARDIOVASCULAR RISK ASSESSMENT

foods, such as eggs, fatty fish, and liver naturally contain vitamin D, but other dietary sources of vitamin D are from fortified foods, like milk and cereals, or from nutritional supplements¹. Most of the body's vitamin D is produced endogenously following exposure of skin to sunlight, thus geography, season, skin tone, and sun exposure are primary predictors of vitamin D nutritional status². Vitamin D obtained from sun is in the form of vitamin D₃ (cholecalciferol), while vitamin D₂ (ergocalciferol) or D₃ may be obtained from dietary sources. Vitamin D₂ differs from vitamin D₃ in that it is derived from dietary ergosterol; it contains a double bond between carbon 22 and 23 and it has an additional methanol group at position 24, while vitamin D₃ is produced by the action of sunlight on 7-dehydrocholesterol. Both

Vitamin D₂ and D₃ are biologically inactive and are activated by two hydroxylation reactions, the first occurring in the liver to form 25(OH)D and the second occurring in the kidney to form the biologically active 1,25-dihydroxyvitamin D [1,25(OH)₂D] (see Figure 1). Since only the hydroxylated forms are active and because these active molecules are produced within the body and have effects in multiple tissues and cell types, it is more accurate to consider 25(OH)D and 1,25(OH)₂D as hormones rather than vitamins.

The main function of vitamin D is to promote calcium absorption in the gut and to maintain adequate blood levels of calcium and phosphorus. If the body is deficient in vitamin D, normal bone




Figure 1. Inactive and active forms of Vitamin D₂ and D₃.

mineralization is compromised and bones may become thin and brittle. Severe deficiency can lead to rickets, with associated skeletal deformities, in children and osteomalacia in adults, which results in both weak bones and muscles. Despite the clear association between vitamin D deficiency and bone disease, much controversy still exists regarding appropriate vitamin D doses needed to avoid disease. Currently, the US Institute of Medicine-National Academy of Sciences recommends a daily intake of 200 IU (5 mg) for individuals < 50 years of age, 400 IU (10 mg) for those 50 to 60 years, and 600 IU (15 mg) for those over 70 years of age.³ However, many experts are recommending that higher daily intakes would be beneficial to most adults. A meta-analysis of 13 randomized placebo controlled studies for hip fracture and non-vertebral fracture risk demonstrated that vitamin D supplementation between 700–800 IU/day reduced the risk of fractures while a dose of 400 IU/day was not sufficient for fracture prevention.⁴

The current upper limit of vitamin D intake is 2000 IU/day due to toxicities that may occur at higher doses. Toxicities are rare but are associated with symptoms caused by marked hypercalcemia. Many have also suggested that the 2000 IU/day recommendation is too conservative. A review of recent clinical trials by Hathcock, et.al.⁵, applying risk assessment methodology used by the Food and Nutrition Board, demonstrated an absence of toxicity in trials conducted on healthy individuals using a vitamin D dose of $\geq 10,000$ IU/day. The authors suggested this value could be used as the upper limit. However concerns about possible toxicity lead most patients and clinicians to use more conservative dosing regimens. Vitamin D intoxication has been clearly documented in experimental studies in animals and in human case reports.⁶ Hypervitaminosis D is associated with increased absorption of calcium and phosphorus, which can lead to hypercalcemia, hypercalciuria, vascular calcification, renal, and even renal failure. It is important to note that most case reports of vitamin D toxicity have resulted in calcification from vitamin D intake far above 10,000 IU/day (5).

Most of the attention concerning vitamin D has been generated over the assessment of vitamin D deficiency. Vitamin D nutritional status is best determined by measurement of 25(OH)D.⁷ At the 13th workshop consensus for vitamin D nutritional guidelines in 2007, studies were summarized indicating that adults should maintain a blood 25(OH)D concentration of approximately 75 nmol/L (30 ng/mL).⁸ There was general consensus that serum vitamin D concentration should meet, or hopefully exceed a minimum desirable concentration of 50 nmol/L (20 ng/mL). Using these levels, it has been estimated that as many as half of the elderly persons in North America are not getting adequate vitamin D to facilitate healthy bone density.⁸

In addition to its primary action on bone metabolism, it is now clear that vitamin D has many non-skeletal actions, and that vitamin D deficiency may be associated with chronic diseases including cancer, autoimmune disease, cardiovascular disease and even psychological illnesses such as schizophrenia and depression.⁹ Here we describe some of the more recent findings associating vitamin D deficiency with various aspects of cardiovascular disease. Vitamin D deficiency has been associated with hypertension, inflammatory markers, diabetes, and the metabolic syndrome, and has recently been associated with increased cardiovascular events and all cause mortality.

Vitamin D and Hypertension

It is well documented that hypertension is a risk factor for cardiovascular disease. For most individuals with hypertension, the cause is unknown and its origin is likely multifaceted. It has been hypothesized that vitamin D deficiency is associated with hypertension, possibly through activation of the renin-angiotensin system. This is due to the finding that 1,25(OH)₂D is a negative endocrine regulator of the renin-angiotensin system.¹⁰ A study describing data from the third National Health and Nutrition Examination Survey (NHANES, 1988-1992) including 16,135 participants > 19 years of age, found that systolic blood pressure (SBP) is inversely

associated with serum vitamin D concentrations in nonhypertensive white persons in the United States.¹¹ Although adjusting for age resulted in loss of significance for the association, concentrations of 25(OH)D > 80 nmol/L decreased the age-related increase in SBP by 20% compared with individuals having 25(OH)D < 50 nmol/L. The authors suggest that future studies should be undertaken to determine the effects of vitamin D supplementation on hypertension.¹¹

Vitamin D, Diabetes, and the Metabolic Syndrome

The association between diabetes and cardiovascular disease is well-established and the presence of diabetes is considered as a coronary heart disease risk equivalent in the National Cholesterol Education Program Adult Treatment Panel III guidelines.¹² A body of research now indicates that vitamin D may play a role in insulin resistance¹³ and diabetes.¹⁴ Although many studies have been published, a few will be highlighted here. Hyppönen and colleagues collected data on the dose and frequency of vitamin D supplementation during the first year of life in 10,366 children born in 1966.¹⁴ By the end of December 1997, 81 of the 10,366 children were diagnosed with diabetes during the study. Regular supplementation with vitamin D during the first year of life was associated with a decreased frequency of type I diabetes (rate ratio = 0.12, 95% CI = 0.03-0.51) even after adjustment for neonatal anthropometric and social characteristics. In 15,088 participants (7186 male and 7902 female) from the NHANES III who had serum 25(OH)D measures, the adjusted prevalence of diabetes mellitus was significantly higher in the first than in the fourth quartile of serum 25(OH)D levels (OR = 1.98, P<0.001).¹⁵ This study also showed significant associations between low levels of 25(OH)D and obesity, hypertension and hypertriglyceridemia. In a meta-analysis published in 2008,¹⁶ Pittas and colleagues searched MEDLINE through January of 2007 for observational studies associating 25(OH)D concentration and type 2 diabetes and for randomized controlled trials of the effect of vitamin D supplementation on outcomes related to glucose

homeostasis. A relatively consistent association between low concentrations of 25(OH)D and the prevalence of type 2 diabetes or the metabolic syndrome was shown for observational studies. Evidence from randomized trials suggested that combined supplementation with vitamin D and calcium may have a role in the prevention of type 2 diabetes mellitus, particularly in high risk populations (i.e. patients with glucose intolerance). The evidence, however, was limited because observational studies often did not adjust for potential confounding factors and intervention trials were often short in duration and/or included few subjects. Thus, although there appears to be an association between vitamin D and diabetes as well as insulin resistance and the metabolic syndrome, more studies are needed to further characterize the importance and extent of these associations.

Vitamin D and inflammation

Since 1999, much work has focused on inflammatory mechanisms that couple dyslipidemia to atherogenesis, and it is now recognized that inflammation plays a role in virtually all phases of atherothrombotic disease.¹⁷ Interest in the role of vitamin D in the immune system was sparked by the finding of vitamin D receptors in peripheral blood monocytes.¹⁸ Subsequently, 1,25(OH)₂D has been shown to inhibit development of some autoimmune diseases including multiple sclerosis and inflammatory bowel disease (19). Interestingly, 1,25(OH)₂D supplementation does not appear to affect other immune mediated diseases like experimental asthma and immunity to infectious organisms.²⁰ Studies in which serum 25(OH)D has been measured along with inflammatory markers (cytokines, CRP, etc.) have not been consistent, with some studies demonstrating an association between low 25(OH)D and inflammatory markers,^{21,22,23,24} while others have not.^{25,26} Thus, the role of vitamin D in inflammatory mediated atherogenesis requires further investigation.

Vitamin D and Cardiovascular disease

Although vitamin D deficiency is most notably characterized by its effect on the musculoskeletal

system, associations between hypovitaminosis D and the cardiovascular system have sparked much interest. As a result, epidemiologic studies examining the association between low serum concentrations of vitamin D and cardiovascular endpoints have been performed. Endpoints that have been investigated include myocardial infarct, stroke, cardiovascular mortality and all cause mortality.

Framingham Offspring study participants (n = 1739, 55% women) without prior cardiovascular disease had serum measurements of 25(OH)D and were then followed for a mean of 5.4 years for cardiovascular events including myocardial infarction, stroke or heart failure.²⁷ In this time period, 120 first cardiovascular events occurred. Individuals with 25(OH)D levels < 15 ng/mL (< 37.5 nmol/L) had a multivariable-adjusted hazard ratio of 1.62 (95% CI 1.11-2.36) for incident cardiovascular events compared to individuals with 25(OH) D > 15 ng/mL. In a nested case control analysis of The Health Professionals Follow-up Study 18,225 men (age 40-75 years) were followed for 10 years.²⁸ Nonfatal myocardial infarction or fatal coronary heart disease occurred in 454 men. Men with 25(OH)D concentrations < 15 ng/mL were at increased risk for myocardial infarction when compared to 900 controls without events who were matched for age, date of blood collection, and smoking status and had 25(OH)D values > 30 ng/ml (relative risk 2.09, 95% CI 1.24-3.54). This difference was significant even after adjustment for family history, lifestyle, laboratory, and other risk factors. Most recently, Vitamin D deficiency has been linked with both cardiovascular mortality and all cause mortality. In a prospective cohort study, 3256 consecutive male and female patients scheduled for coronary angiography were followed for a median of 7.7 years with 737 deaths including 463 from cardiovascular causes.²⁹ Compared to patients with 25(OH)D concentrations in the highest quartile (median 28.4 ng/mL or 71 nmol/L), patients in the lower two quartiles (median 7.6 and 13.3 ng/mL or 19.0 and 33.3 nmol/L) had higher hazard ratios for all cause mortality (HR = 2.08, 95% CI = 1.60-2.70 and HR = 1.53, 95% CI =

1.17-2.01, respectively) and for cardiovascular mortality (HR = 2.22, 95% CI = 1.57-3.13 and HR = 1.82, 95% CI = 1.29-2.58, respectively).

Although these studies demonstrate significant associations between 25(OH)D concentrations and cardiovascular events, they do not confirm a direct causal relationship. Consideration should be given to whether vitamin D deficiency is a cause or an effect of cardiovascular disease. Groups at risk for developing adverse cardiovascular events include older adults and individuals with obesity and a sedentary lifestyle who have poor dietary habits. These same individuals are likely at risk for vitamin D deficiency because their sedentary life style includes limited sun exposure and poor dietary habits that may result in decreased intake of vitamin D. Determining a causal effect between vitamin D deficiency and cardiovascular events would require large prospective trials designed to demonstrate that correcting vitamin D deficiency reduces adverse cardiovascular events.

Monitoring Vitamin D status

Because the prevalence of vitamin D deficiency in the general population is well-publicized, laboratory requests for the measurement of vitamin D have increased dramatically. The most widely used indicator of vitamin D status is 25(OH)D concentration in plasma or serum. However, several studies have reported discrepancies between the assays used.^{30,31} Methods used include low and high throughput RIAs, automated chemiluminescent immunoassays, HPLC, and liquid chromatography tandem mass spectrometry (LC-MS/MS).⁷ Although the reasons for the noted discrepancies in methods are not fully understood, possible causes include the ability of the assays to respond equally to 25(OH)D₂ and 25(OH)D₃ as well as the lack of a standard reference material (SRM). It is also important to note that some labs and assays report total vitamin-D whereas others discriminate between 1,25(OH)₂D and 25(OH)D. In response to the apparent lack of standardization, the National Institute of Standards and Technology (NIST) and the National Institutes of Health's Office of Dietary Supplements have been

FOCUS: CARDIOVASCULAR RISK ASSESSMENT

working together to develop a reference material consisting of four pools of fresh-frozen serum, each pool having different concentrations of 25(OH)D₂, 25(OH)D₃ and one pool containing the recently discovered metabolite, 3-epi-25(OH) D₃.³² This new SRM should be very helpful as it can be utilized by investigators to validate new methods, as well as serve as a reproducible point of comparison for existing methods, facilitating method standardization.

CONCLUSIONS

Vitamin D deficiency has been associated with hypertension, inflammatory markers, diabetes, metabolic syndrome, and has recently been associated with increased cardiovascular events and all cause mortality. This is an exciting finding, as it leads to the possibility that correction of vitamin D deficiency could improve cardiovascular outcomes. However, although lower concentrations of vitamin D have been associated with adverse outcomes, we do not yet have prospective controlled studies demonstrating that supplementation of vitamin D in patients with apparent deficiency is associated with improved outcomes. Although observational studies suggest this may be the case, caution should be taken not to draw causal inferences from observational studies, even if the sample size is large and the duration of follow-up long. We need only to be reminded about the results of studies looking at folate/B vitamin supplementation and hormone replacement therapy to realize the importance of carrying out such studies.


Clin Lab Sci encourages readers to respond with thoughts, questions, or comments regarding this Focus section. Email responses to westminsterpublishers@comcast.net. In the subject line, please type "CLIN LAB SCI 22(4) FO CARDIOVASCULAR RISK". Selected responses will appear in the Dialogue and Discussion section in a future issue. Responses may be edited for length and clarity. We look forward to hearing from you.

REFERENCES

1. Endres DB and Rude RK, in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th edition. Burtis CA, Ashwood ER, Bruns DE, eds. 2008; 1920–6.
2. Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. *Am J Clin Nutr* 2007;85:649–50.
3. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press, 1997.
4. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA* 2005;293:2257–64.
5. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. *Am J Clin Nutr* 2007;85:6–18.
6. Zittermann A, Koerfer R. Protective and toxic effects of vitamin D on vascular calcification: Clinical implications. *Mol Aspects Med*. 2008 Dec;29(6):423–32.
7. Singh RJ. Are clinical laboratories prepared for accurate testing of 25-hydroxy vitamin D? *Clin Chem* 2008;54:22–3.
8. Norman AW, Bouillon R, Whiting SJ, et al. 13th Workshop consensus for vitamin D nutritional guidelines. *J Steroid Biochem Mol Biol* 2007;103:204–5.
9. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;357:266–81.
10. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 2002;110:229–38.
11. Judd SE, Nanes MS, Ziegler TR, et al. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 2008;87:136–41.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486–97.
13. Chiu KC, Chu A, Go VL, Saad MF. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2007;167:1159–65.
14. Hyppönen E, Läärä E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet*. 2001;358(9292):1500–3.
15. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2007;167:1159–65.
16. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J Clin Endocrinol Metab* 2007;92:2017–29.
17. Libby P. Inflammation in atherosclerosis. *Nature* 2002;420:868–74.

FOCUS: CARDIOVASCULAR RISK ASSESSMENT


18. Bhalla AK, Amento EP, Clemens TL, et al. Specific high-affinity receptors for 1,25-dihydroxyvitamin D₃ in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. *J Clin Endocrinol Metab* 1983;57:1308–10.
19. Cantorna MT, Yu S, Bruce D. The paradoxical effects of vitamin D on type 1 mediated immunity. *Mol Aspects Med*. 2008 Dec;29(6):369–75.
20. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D₃, and the immune system. *Am J Clin Nutr* 2004;80(6 Suppl):1717–20S.
21. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. *Arch Intern Med* 2008;168:1340–9.
22. Targher G, Bertolini L, Padovani R, et al. Serum 25-hydroxyvitamin D₃ concentrations and carotid artery intima-media thickness among type 2 diabetic patients *Clin Endocrinol (Oxf)* 2006;65:593–7.
23. Peterson CA, Heffernan ME. Serum tumor necrosis factor- α concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. *J Inflamm (Lond)* 2008;5:10.
24. Bonakdaran S, Varasteh A. Correlation between serum 25 hydroxy vitamin D₃ and laboratory risk markers of cardiovascular diseases in type 2 diabetic patients. *Saudi Med J* 2009;30:509–14.
25. Ewers B, Gasbjerg A, Zerahn B, Marckmann P. Impact of vitamin D status and obesity on C-reactive protein in kidney-transplant patients. *J Ren Nutr* 2008;18:294–300.
26. Michos ED, Streeten EA, Ryan KA, et al. Serum 25-hydroxyvitamin D levels are not associated with subclinical vascular disease or C-reactive protein in the old order Amish. *Calcif Tissue Int* 2009;84(3):195–202.
27. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. *Circulation* 2008;117:503–11.
28. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. *Arch Intern Med* 2008;168:1174–80.
29. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. *Arch Intern Med* 2008;168:1340–9.
30. Carter GD, Carter R, Jones J, Berry J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. *Clin Chem* 2004;50:2195–7.
31. Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. *J Clin Endocrinol Metab* 2004;89:3152–7.
32. Phinney KW. Development of a standard reference material for vitamin D in serum. *Am J Clin Nutr* 2008;88:511S–512S.



ASCLS

Education Connections


Designed to help continue
your education



Take a closer look at these New Titles --

- **Clinical Chemistry Reviews - GI, Liver and Pancreas; the 8th of 10 modules now available.** By Larry Kaplan, PhD & Amadeo Pesce, PhD; CD
- **Methods in Clinical Chemistry - 144 methods of analysis describing current methodology, analytical quality goals and performance data; excellent lab resource;** *Pesce Kaplan Publishers*; CD or book

- **Patient Safety: Events Management in the Clinical Laboratory - a new ASCLS online course - easy to navigate.** Learn to get the most information possible from events that occur and use tools and methods to create a safer environment. Written by ASCLS experts!
- **Shipping Infectious and Biological Substances Quiz - game show format of questions and answers.** A fun way to test knowledge. By Terry Jo Gile; CD



For more information, visit www.ascls.org, click on Continuing Education/What's New? or email joanp@ascls.org.

American Society for Clinical Laboratory Science, 6701 Democracy Blvd., Suite 300, Bethesda, MD 20817